TR200200401T2 - PEG-IFN-a ile birlikte mikofenolat mofetil - Google Patents

PEG-IFN-a ile birlikte mikofenolat mofetil

Info

Publication number
TR200200401T2
TR200200401T2 TR2002/00401T TR200200401T TR200200401T2 TR 200200401 T2 TR200200401 T2 TR 200200401T2 TR 2002/00401 T TR2002/00401 T TR 2002/00401T TR 200200401 T TR200200401 T TR 200200401T TR 200200401 T2 TR200200401 T2 TR 200200401T2
Authority
TR
Turkey
Prior art keywords
ifn
peg
mycophenolate mofetil
treatment
therapeutically effective
Prior art date
Application number
TR2002/00401T
Other languages
English (en)
Turkish (tr)
Inventor
Catherine Graves Mary
Ghristopher Pappas Stephen
Zahm Friederike
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200200401T2 publication Critical patent/TR200200401T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TR2002/00401T 1999-08-13 2000-08-08 PEG-IFN-a ile birlikte mikofenolat mofetil TR200200401T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08

Publications (1)

Publication Number Publication Date
TR200200401T2 true TR200200401T2 (tr) 2002-06-21

Family

ID=29762814

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00401T TR200200401T2 (tr) 1999-08-13 2000-08-08 PEG-IFN-a ile birlikte mikofenolat mofetil

Country Status (14)

Country Link
EP (1) EP1220683A2 (xx)
JP (1) JP2003507339A (xx)
CN (1) CN1368887A (xx)
AU (1) AU7408200A (xx)
BR (1) BR0013252A (xx)
CA (1) CA2380653A1 (xx)
HU (1) HUP0202525A3 (xx)
MX (1) MXPA02001296A (xx)
PE (1) PE20010490A1 (xx)
PL (1) PL357367A1 (xx)
RU (1) RU2002105485A (xx)
TR (1) TR200200401T2 (xx)
WO (1) WO2001012214A2 (xx)
ZA (1) ZA200200280B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
KR20070045244A (ko) * 2004-08-12 2007-05-02 쉐링 코포레이션 안정한 페길화된 인터페론 제형
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2010110503A1 (ko) * 2009-03-27 2010-09-30 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
EP3215193B1 (en) * 2014-11-06 2023-10-04 PharmaEssentia Corporation Dosage regimen for pegylated interferon
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
WO2001012214A2 (en) 2001-02-22
JP2003507339A (ja) 2003-02-25
ZA200200280B (en) 2003-04-11
HUP0202525A2 (hu) 2002-11-28
BR0013252A (pt) 2002-04-16
CA2380653A1 (en) 2001-02-22
CN1368887A (zh) 2002-09-11
WO2001012214A3 (en) 2001-10-04
AU7408200A (en) 2001-03-13
PE20010490A1 (es) 2001-04-27
HUP0202525A3 (en) 2003-11-28
MXPA02001296A (es) 2002-07-22
EP1220683A2 (en) 2002-07-10
RU2002105485A (ru) 2004-01-27
PL357367A1 (en) 2004-07-26

Similar Documents

Publication Publication Date Title
RU2003119460A (ru) Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с
TR200200401T2 (tr) PEG-IFN-a ile birlikte mikofenolat mofetil
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
DK275488D0 (da) Indolonderivater
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
ES2169762T3 (es) Liberacion continua de peptidos a partir de composiciones farmaceuticas.
KR920700200A (ko) 19-노르-비타민 d 화합물
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
ATE87484T1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
TR200101633T2 (tr) Farmasötik bileşim
ATE257704T1 (de) Pharmazeutische zusammensetzungen enthaltend norastemizol.
NO20003313D0 (no) Terapeutiske midler
RU2004137823A (ru) Терапевтическое средство против гиперкальциемического криза
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
JP2002544227A5 (xx)
RU2004131214A (ru) Способы лечения когнитивных расстройств
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
Newell Pharmacokinetically guided dose escalation in phase I clinical trials: Commentary and proposed guidelines.
KR890012942A (ko) 5-치환된 오르니틴 유도체
RU2006101061A (ru) Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела